Abiraterone Acetate for Metastatic Castrate Sensitive Prostate Cancer


( Last Updated : June 2, 2021)
Project Line:
Health Technology Review
Project Sub Line:
Peer-reviewed Summary with Critical Appraisal
Project Number:
RD0060

Details


Question

1. What is the clinical effectiveness of abiraterone acetate combined with ADT for mCSPC?
2. What is the cost-effectiveness of abiraterone acetate combined with ADT for mCSPC?

Key Message

The use of abiraterone acetate for the treatment of metastatic castration-sensitive prostate cancer is clinically effective. Compared with standard of care, abiraterone acetate was associated with increased overall survival, increased prostate cancerspecific survival, increased progression-free survival, and improved quality of life. Patients treated with abiraterone acetate were at higher risk for grade III to grade V adverse events (severe, life-threatening, or fatal) and were more likely to discontinue treatment compared with standard of care. The incremental cost-effectiveness ratios for both brand and generic abiraterone acetate were estimated to be higher than common willingness-to-pay thresholds.